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The clinical value of antimonial drugs, the mainstay therapy for leishmaniasis, is now threatened by the
emergence of acquired drug resistance, and a comprehensive understanding of the underlying mechanisms is
required. Using the model organism Leishmania tarentolae, we have examined the role of trypanothione
S-transferase (TST) in trivalent antimony [Sb(III)] resistance. TST has S-transferase activity with substrates
such as chlorodinitrobenzene as well as peroxidase activity with alkyl and aryl hydroperoxides but not with
hydrogen peroxide. Although S-transferase activity and TST protein levels were unchanged in Sb(III)-sensitive
and -resistant lines, rates of metabolism of hydrogen peroxide, t-butyl hydroperoxide, and cumene hydroper-
oxide were significantly increased. Elevated peroxidase activities were shown to be both trypanothione and
tryparedoxin dependent and were associated with the overexpression of classical tryparedoxin peroxidase
(TryP) in the cytosol of L. tarentolae. The role of TryP in Sb(III) resistance was verified by overexpression of
the recombinant Leishmania major protein in Sb(III)-sensitive promastigotes. An approximate twofold increase
in the level of TryP activity in this transgenic cell line was accompanied by a significant decrease in sensitivity
to Sb(III) (twofold; P < 0.001). Overexpression of an enzymatically inactive TryP failed to result in Sb(III)
resistance. This indicates that TryP-dependent resistance is not due to sequestration of Sb(III) and suggests
that enhanced antioxidant defenses may well be a key feature of mechanisms of clinical resistance to antimo-
nial drugs.
The protozoan parasite Leishmania elicits a broad range of
human and animal infections ranging from life-threatening
kala azar to disfiguring mucocutaneous and cutaneous forms of
the disease. The World Health Organization reports over 12
million cases of all forms of leishmaniasis worldwide with
500,000 new infections each year, resulting in an annual death
toll of 59,000 (39). Chemotherapy has proven to be the only
effective way of controlling infections and is highly dependent
upon antimony-containing drugs such as sodium stiboglu-
conate (Pentostam). However, after more than half a century
as the mainstay therapy for leishmaniasis, the clinical value of
antimonials is now threatened due to the emergence of ac-
quired drug resistance (5). In the past 15 years, failure of
antimonials in regions of Bihar, India, where the disease is
endemic has become an escalating problem, with primary un-
responsiveness reportedly of over 50% (35). Identifying ways
in which current antimony therapies can be adapted and im-
proved to circumvent resistance is now a matter of urgency.
The unique thiol metabolism of Leishmania is thought to
play a pivotal role in the mechanisms of action of antimonial
drugs. In these parasites, the major low-molecular-mass thiol is
trypanothione (T[SH]2) [N
1,N8-bis(glutathionyl)spermidine],
in contrast to most other organisms, which utilize glutathione
(-L-glutamyl-L-cysteinylglycine) (GSH) (7). Key functions of
this essential metabolite include maintenance of thiol redox
homeostasis, as well as well as defense against chemical (37)
and oxidative stress (7). Antimonial drugs are administered as
pentavalent antimony [Sb[V]), a prodrug requiring conversion
to the trivalent form [Sb(III)], before becoming biologically
active. However, the site of reduction (host macrophage, amas-
tigote, or both) and mechanism of reduction (enzymatic or
nonenzymatic) remain unclear (10, 31). Sb(III) interferes di-
rectly with thiol metabolism, decreasing thiol-buffering capac-
ity in drug-sensitive Leishmania donovani by inducing rapid
efflux of intracellular T[SH]2 and GSH (41). Sb(III) also in-
hibits T[SH]2 reductase in intact cells, resulting in the accu-
mulation of the disulfide forms of both T[SH]2 (T[S]2) and
GSH. These two mechanisms act synergistically against Leish-
mania parasites, leading to a lethal imbalance in thiol ho-
meostasis.
The ability to generate drug-resistant Leishmania lines in the
laboratory, through stepwise exposure to Sb(III), has greatly
facilitated the study of antimonial resistance mechanisms (2,
26). Indeed, several key features of in vitro drug resistance
have since been identified in resistant clinical isolates (23, 25).
A considerable body of evidence places thiol metabolism at the
center of both clinical and laboratory-generated resistance
mechanisms (2, 23). Elevated levels of T[SH]2 and GSH, re-
sulting from the overexpression of the rate-limiting enzymes
involved in the synthesis of GSH (-glutamylcysteine synthase
[GCS]) (11) and polyamines (ornithine decarboxylase
[ODC]) (13), the two precursor metabolites of T[SH]2, have
been observed in several laboratory-induced resistant lines of
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Leishmania. Interestingly, elevated thiols alone do not result in
Sb(III) resistance; however, modulation of T[SH]2 levels,
through the use of inhibitors of thiol biosynthesis, reverts re-
sistance (12) indicating that antimonial drug resistance is mul-
tifactorial. Overexpression of PgpA, an intracellular metal-
thiol transporter from the ATP-binding cassette transporter
family, has also been demonstrated to play a key role in resis-
tance (11, 12). Cotransfection of genes encoding GCS and
PgpA confers antimony resistance in a synergistic manner in
partially revertant Leishmania parasites (12). Collectively,
these studies have led researchers to hypothesize that Sb(III) is
detoxified from resistant parasites via the formation of Sb(III)-
thiol complexes which are then sequestered in an intracellular
vacuolar compartment by PgpA.
In addition to elevated intracellular thiols and elevated
PgpA, a third resistance determinant has been identified. In
work with the model organism Leishmania tarentolae, Haimeur
and colleagues demonstrated that, despite having lost amplifi-
cation of GCS, ODC, and PgpA (12), a formerly Sb(III)-
resistant revertant cell line retained significant resistance.
These researchers hypothesized that an enzyme facilitating the
formation of thiol-Sb(III) conjugates for subsequent seques-
tration by PgpA may well be responsible. Indeed, GSH S-
transferase, which catalyzes the conjugation of xenobiotics to
GSH in mammalian cells, is elevated in arsenite-resistant Chi-
nese hamster ovary cells (22). Since GSH S-transferase is not
detectable in Leishmania spp., it has been suggested that the
recently identified T[SH]2 S-transferase (TST) enzyme may
facilitate this conjugation in Sb(III)-resistant Leishmania par-
asites (12). Unusually, TST activity in these cells is associated
with the eukaryotic translation elongation factor 1B (38). In
the current study we investigate the potential role of TST
activity in antimony resistance.
MATERIALS AND METHODS
Cell lines and culture conditions. The cell lines used in this study were
wild-type L. tarentolae (TarII), the Sb(III)-resistant TarII Sb1.1, and its partially
resistant revertant TarII Sb1.1rev (12). Promastigotes were propagated in
SDM-79 medium supplemented with 10% (vol/vol) fetal calf serum and grown at
24°C with shaking. TarII Sb1.1 cells were grown in the presence of 250 M
potassium antimony tartrate to maintain resistance.
In order to examine the effects of antimony on growth, triplicate cultures
containing Sb(III) (as potassium antimony tartrate) were seeded at 5  105
promastigotes ml1. Cell densities were determined microscopically after culture
for 72 h, and 50% effective concentrations (EC50s) were determined using the
EC50 four-parameter equation provided with GraFit.
Analysis of intracellular thiols. Mid-log-phase promastigotes (5  107) were
collected by centrifugation (1,600  g, 10 min, 4°C) and derivatized with mono-
bromobimane, as described previously (32). Acid-soluble thiols were separated
by ion-paired, reverse-phase high-pressure liquid chromatography on a Beckman
Ultrasphere C18 column using a Beckman System Gold instrument fitted with a
Gilson-121 fluorometer.
Cell lysis. Frozen L. tarentolae cell pellets were thawed on ice and resuspended
in an equal volume of ice-cold lysis buffer (50 mM potassium phosphate [pH 7.0],
1 mM EDTA). The organisms were lysed under pressure (30 kpsi) using a
one-shot cell disruptor (Constant Systems). After centrifugation (100,000  g,
1 h, 4°C), the clarified extracts were dialyzed against the same buffer (4 times, 50
volumes) and assayed immediately for enzyme activity.
Enzyme assays. T[SH]2 reductase was assayed spectrophotometrically at 340
nm in 40 mM Na HEPES (pH 7.5), 1 mM EDTA, 150 M NADPH, and 100
M T[S]2 (6). TST was assayed in 100 mM Na phosphate (pH 6.5) with 400 M
1-chloro-2,4-dinitrobenzene and 400 M T[SH]2 as substrates. The rate of for-
mation of the T[SH]2 S-dinitrobenzene conjugate was followed at 340 nm, using
the published extinction coefficient of 9.2 mM cm1 (36). T[SH]2-dependent
peroxidase activities were measured as previously described (15). Briefly, the
rates of metabolism of hydrogen peroxide (H2O2), t-butyl hydroperoxide
(tBuOOH), and cumene hydroperoxide (CuOOH) were monitored in assays
containing 50 mM K phosphate (pH 7.0), 0.05 mM T[SH]2, 0.05 mM peroxide,
0.25 mM NADPH, and 0.3 U ml1 T[SH]2 reductase. Where specified, assays
were supplemented with 1 M recombinant L. major tryparedoxin. Peroxidase
activity was measured by the consumption of NADPH at 340 nm. All enzymatic
activities were proportional to the amount of protein assayed and heat labile.
Western analysis of whole-cell lysates. Polyclonal antisera against Leishmania
major tryparedoxin, tryparedoxin peroxidase (type I), tryparedoxin peroxidase
(type II), and T[SH]2 synthetase and Trypanosoma brucei T[SH]2 reductase were
raised in adult male Wistar rats. An initial injection of 100 g of purified antigen,
emulsified in complete Freund’s adjuvant, was followed by two identical booster
injections of antigen emulsified in Freund’s incomplete adjuvant at 2-week in-
tervals.
Mid-log-phase L. tarentolae promastigotes (1  107 ml1) were pelleted by
centrifugation (1,600  g, 10 min, 4°C), washed twice in phosphate-buffered
saline (PBS), and resuspended directly in 2 Laemmli buffer containing 200 mM
dithiothreitol. Whole-cell extracts (1  107 parasites per lane) were then sepa-
rated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subse-
quently transferred onto nitrocellulose. After blocking with 5% skim milk in PBS
at room temperature for 1 h, blots were incubated with polyclonal antiserum at
room temperature for 1 h, washed in PBS containing 0.1% (vol/vol) Tween 20,
and then incubated with a secondary rabbit anti-rat (immunoglobulin G [IgG])
antibody (1/10,000 dilution). Immunoblots were developed using the ECL Plus
enhanced chemiluminescence system from Amersham Biosciences. Identical im-
munoblots were prepared and probed with the following primary antisera:
tryparedoxin (1/700 dilution), T[SH]2 synthetase (1/500 dilution), T[SH]2 reduc-
tase (1/500 dilution), tryparedoxin peroxidase type I (1/5000 dilution), trypare-
doxin peroxidase type II (1/1000 dilution), and TST (1/300 dilution) (38). The
relative intensities of protein bands in each Western blot were determined by
densitometry using Labworks software (UVP).
Subcellular fractionation. Subcellular fractions of L. tarentolae were prepared
as previously described (27). Each fraction (30 g) was then separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto nitro-
cellulose. After blocking, the blot was probed with L. major tryparedoxin per-
oxidase (type I) polyclonal antiserum and detected by chemiluminescence, as
described above. Identical immunoblots were probed using the following primary
antibodies: anti-Hsp60 monoclonal antibody (1/5,000 dilution; Stressgen); anti-L.
major T[SH]2 synthetase antiserum (1/1,000 dilution) (27), and anti-T. brucei BiP
antiserum (1/5,000 dilution) (1). Rabbit anti-rat (IgG) antibody (Dako; 1/10,000
dilution) and anti-mouse (IgG-horseradish peroxidase) antibody (Sigma;
1/10,000 dilution) were used as secondary antibodies where appropriate, and
immunoblots were once again developed by enhanced chemiluminescence.
Cloning and expression of L. major tryparedoxin peroxidase in L. tarentolae.
The L. major tryparedoxin peroxidase gene (LmjF15.1120) was amplified by PCR
from L. major Friedlin genomic DNA using the sense primer 5-GGATCCAT
GTCCTGCGGTAACGCCAAGATCAAC-3 and the antisense primer
5-GGATCCTTACTGCTTGCTGAAGTATCCCTCGAC-3, both with addi-
tional BamHI sites (underlined). The PCR product was then cloned into the
pCR-Blunt II-TOPO vector (Invitrogen) and sequenced. The pCR-Blunt II-
TOPO-LmTryP construct was then digested with BamHI and the fragment
cloned into the pIR1SAT expression vector, resulting in a pIR1SAT-LmTryP
construct. Mid-log-phase L. tarentolae promastigotes (wild type, TarII) were
transfected with either pIR1SAT-LmTryP or with the empty vector by electro-
poration using a high-voltage protocol (28). Following transfection, cells were
allowed to grow for 16 to 24 h in SDM-79 medium with 10% fetal calf serum and
then plated on semisolid medium containing 1% Noble agar (Difco) and 100 g
ml1 nourseothricin (Jena Bioscience, Germany). Individual colonies were
picked and grown in liquid medium. Clones were maintained in selective medium
and then removed from drug selection for one passage prior to experiments.
Cloning and expression of an inactive L. major tryparedoxin peroxidase gene
mutant in L. tarentolae. Site-directed mutagenesis was carried out following the
QuikChange protocol (Stratagene) and using the KOD HotStart DNA polymer-
ase (Novagen). Using the pIRSAT-LmTryP construct as a template, an R128D
mutant of L. major TryP was generated by PCR with the sense primer 5
GCCAGGGCGTGCCTACGACGGTCTCTTCATCATCG and antisense
primer 5 CGATGATGAAGAGACCGTCGTAGGCCACGCCCTGGC, with
mutated bases underlined. The modified construct, pIR1SAT-LmTryP(R128D),
was transfected into mid-log-phase L. tarentolae promastigotes (wild type, TarII)
as described above.
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Intracellular thiol levels in Sb(III)-sensitive and -resistant
L. tarentolae. A comprehensive understanding of the mecha-
nisms of resistance to antimonials is crucial, not only in the
ongoing fight to save these mainstay therapies but also for the
future design of more effective anti-Leishmania drugs. With
this in mind, the previously characterized L. tarentolae TarII
(wild type), TarII Sb1.1 [Sb(III)-resistant] and TarII Sb1.1rev
[Sb(III)-resistant revertant] cell lines were used to examine the
putative role of TST in Sb(III) resistance (12). Initially, the
relative Sb(III) sensitivities of all three cell lines were deter-
mined in potassium antimony tartrate. In keeping with previ-
ously published data (12), the Sb(III)-resistant cell line was
approximately 50-fold less sensitive to potassium antimony tar-
trate than the parental wild-type cells, while the revertant cell
line was 8-fold less sensitive (Table 1).
Intracellular thiol levels in the parental wild-type, revertant,
and resistant cell lines were determined (Table 1). In contrast
to the data of Haimeur and Ouellette (14), we could detect no
significant difference in the thiol levels of revertant versus
wild-type cells. However, Sb(III)-resistant cells maintained sig-
nificantly higher levels of GSH, GspdSH, and T[SH]2 (P 
0.0001). Indeed, the levels of total acid-soluble low-molecular-
mass thiol groups were approximately 7.5-fold higher in TarII
Sb1.1 than in revertant and wild-type cells, suggesting that
elevated intracellular thiol levels are associated with high levels
of Sb(III) resistance but are not responsible for the residual
resistance of the Sb1.1rev cell line.
Since Sb(III) is known to induce the rapid efflux of intracel-
lular GSH and T[SH]2 in Leishmania donovani (41), thiols in
Sb(III)-resistant promastigotes were reanalyzed following
growth for two passages in the absence of Sb(III). Interest-
ingly, these cells maintained even higher levels of intracellular
thiols (37.1 nmol 108 cells1 total SH) than the original resis-
tant cell line (30.3 nmol 108 cells1 total SH), presumably due
to continued thiol synthesis in the absence of thiol-Sb(III)
conjugate efflux.
TST activity in clarified L tarentolae lysates. Clarified ex-
tracts of all three L. tarentolae cell lines were prepared and
assayed directly for TST activity (Table 2). Using 1-chloro-2,4-
dinitrobenzene as a substrate, no difference in the TST activ-
ities of extracts of wild-type, revertant, and resistant promas-
tigotes could be detected, suggesting that TST overexpression
is not associated with Sb(III) resistance in these parasites.
T[SH]2 reductase (TryR) activity was similar in all three ex-
tracts, suggesting that an elevated TryR level is not responsible
for residual resistance either.
In our previous studies we demonstrated that L. major TST
displays T[SH]2-dependent peroxidase activity against a variety
of organic hydroperoxides. To further verify that TST is not an
Sb(III) resistance determinant in L. tarentolae, the rates of
metabolism of H2O2, CuOOH, and tBuOOH were measured
in dialyzed extracts. Unexpectedly, the rates of metabolism of
H2O2 and tBuOOH were considerably higher in the resistant
and revertant lysates than in the wild type (Table 2). Specifi-
cally, H2O2 metabolism was enhanced 4-fold and 8.5-fold in
Sb1.1rev and Sb1.1 extracts, respectively, in keeping with the
8-fold- and 50-fold-increased levels of Sb(III) resistance found
in whole cells. CuOOH was less efficiently reduced. Since L.
major TST is known to preferentially metabolize hydrophobic
hydroperoxides and is unable to utilize hydrogen peroxide as a
substrate (38), it is unlikely that this enzyme is responsible for
the peroxidase activities detected in these extracts.
The apparent lack of TST involvement in Sb(III) resistance
is in marked contrast to the resistance mechanisms employed
by mammalian cells, in which GSH S-transferases accelerate
the detoxification of the related metalloid As(III) via conjuga-
tion to GSH (18). Although the spontaneous formation of
Sb(III)-thiol (GSH and T[SH]2) complexes has been demon-
strated (34), some researchers have suggested that an enzyme
such as TST may be required to accelerate this reaction in vivo
(12). In light of the elevated levels of intracellular thiols and
TABLE 1. Intracellular thiol levels in Sb(III)-sensitive L. tarentolae TarII (wild type), Sb(III)-resistant TarII Sb1.1, and partially resistant
revertant TarII Sb1.1rev
Cell line EC50 (g ml1)
Thiol content (nmol 108 cells1)a
GSH GspdSH TSH	2 Total SH
TarII (wild type) 7.35 
 0.14 0.75 
 0.04 0.325 
 0.08 1.6 
 0.03 4.28
TarII Sb1.1rev (revertant) 56.5 
 1.9c 0.8 
 0.05c 0.37 
 0.02c 1.70 
 0.07c 4.56c
TarII Sb1.1 (resistant) 377 
 38.4d 8.76 
 0.11d 1.4 
 0.01d 10.05 
 0.1d 30.26d
TarII Sb1.1  Sbb Not applicable 11.1 
 0.2d 1.8 
 0.09d 12.1 
 0.15d 37.1d
a Thiol levels represent the means 
 standard deviations from triplicate determinations.
b Cells grown in the absence of Sb(III) for two passages prior to analysis.
c Not significantly different from wild-type values (P  0.05).
d Significantly different from wild-type value (P  0.0001).
TABLE 2. Specific activities of TSH	2 reductase, TST, and TSH	2-
dependent peroxidase in L. tarentolae soluble extracts
Enzymatic activity Substrate




TSH	2 reductase TS	2 112 




TST CDNB 1.2 
 0.5 1.6 










 0.1 3.1 
 0.1c 8.9 
 0.4c
tBuOOH 1.9 
 0.2 8.8 
 0.2c 22.4 
 0.4c
a All enzymatic activities were assayed as described in Materials and Methods
and were corrected for nonenzymatic background rates. Values are means 

standard deviations.
b P  0.05 compared to wild-type value.
c P  0.0001 compared to wild-type value.
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overexpression of the metal-thiol transporter PgpA in resistant
Leishmania parasites, the ability to more rapidly form Sb(III)-
thiol conjugates for detoxification would be predicted to en-
hance Sb(III) resistance. However, the absence of accompany-
ing TST overexpression in these cell lines implies that TST is
not responsible for the resistance phenotype.
Tryparedoxin-dependent peroxidase activity in clarified ex-
tracts. In Leishmania and other trypanosomatids, enzymes of
the tryparedoxin peroxidase family are thought to be princi-
pally responsible for detoxification of peroxides (9). This fam-
ily consists of two classes of 2-Cys peroxidases, the decameric
type I tryparedoxin peroxidase (TryP) (8, 20) and the mono-
meric type II tryparedoxin peroxidase (TDPX), a cysteine ho-
mologue of the classical GSH peroxidases (16, 29, 30). Both
enzymes obtain their reducing equivalents from T[SH]2 via the
dithiol protein tryparedoxin (TryX). To establish whether a
TryX-dependent peroxidase was involved in Sb(III) resistance,
clarified extracts were assayed for peroxidase activity following
the addition of exogenous recombinant L. major TryX (Fig. 1).
In the presence of TryX, peroxidase activities in all three
extracts, and against all substrates, were at least doubled (Ta-
ble 2). However, metabolism of H2O2, tBuOOH, and CuOOH
remained significantly higher in revertant and resistant cell
extracts compared to wild type (P  0.0001). These observa-
tions suggest that enhanced peroxide metabolism in Sb(III)-
resistant cells is TryX dependent and that TryX is rate limiting
under these assay conditions. TryPs from several Leishmania
spp. have shown susceptibility to inactivation following expo-
sure to high concentrations of hydrophobic peroxides (3).
Therefore, it was interesting to note that preincubation with 1
mM CuOOH inactivated the elevated peroxidase activities in
revertant and resistant extracts (data not shown).
Western analysis of whole cell lysates. Immunoblots of L.
tarentolae promastigote whole-cell lysates were probed with a
series of polyclonal antisera against all the enzymes of the
tryparedoxin peroxidase pathway (Fig. 2). In keeping with our
enzymatic analysis of whole-cell lysates, TST and TryR protein
levels were similar in wild-type, revertant, and resistant cell
lines. Surprisingly, levels of TryS protein were increased 2.5-
fold in the resistant cell line but not in the revertant. Sb(III) up
to 1 mM had no inhibitory effect on TryS activity, indicating
that TryS, like ODC (spermidine synthesis) and GCS (GSH
synthesis) is a critical, rate-limiting step in T[SH]2 biosynthesis
in highly resistant lines. Although there was no apparent asso-
ciation between Sb(III) tolerance and the levels of TryX or the
recently characterized TDPX (19, 30), levels of TryP were
elevated 2.8-fold and 8.9-fold (as determined by densitometry)
in the revertant and resistant lysates, respectively. Overexpres-
sion of TryP protein in the revertant and resistant parasites
correlates well with the fourfold and eightfold increases in
peroxidase activity (Table 2 and Fig. 1).
Western analysis of Sb(III)-sensitive and -resistant L. taren-
tolae subcellular fractions. TryP localizes to both the mito-
chondria and cytosol of Leishmania parasites (4). To deter-
mine whether overexpression of TryP in a specific cellular
location was associated with Sb(III) resistance, crude subcel-
lular fractions of both wild-type and resistant L. tarentolae were
prepared and immunoblots of each fraction were probed with
an L. major TryP-specific polyclonal antiserum known to cross-
react with both cytosolic and mitochondrial enzymes (Fig. 3).
The purity of each fraction was demonstrated using antibodies
against marker proteins in each subcellular location. The en-
doplasmic reticulum-localized BiP protein (immunoglobulin
heavy chain-binding protein) was used as a marker for the
microsomal fraction, while Hsp60 and TryS were used as
marker proteins for the large granular and cytosolic fractions,
respectively (27). As expected, TryP was found in both the
cytosolic and large granular fractions of both cell lines. The
levels of mitochondrial TryP were marginally higher in resis-
tant than in wild-type L. tarentolae (1.8-fold); however, cyto-
solic TryP levels were considerably higher in the Sb(III)-resis-
tant line (6.5-fold). Specific overexpression of cytosolic TryP
was also observed in revertant parasites (data not shown).
These data suggest that overexpression of a TryP localized to
the cytosol of L. tarentolae is associated with Sb(III) resistance.
Interestingly, Southern analysis of genomic DNA isolated from
wild-type, revertant, and resistant cells confirmed that in-
FIG. 1. Tryparedoxin-dependent peroxidase activity in L. tarentolae
clarified lysates. Metabolism of hydrogen peroxide (white bars),
tBuOOH (gray bars), and CuOOH (black bars) in wild-type (WT),
revertant (REV), and resistant (RES) extracts were measured in the
presence of 1 M recombinant L. major tryparedoxin. Data represent
the means 
 standard deviations from triplicate determinations. ***,
P  0.0001.
FIG. 2. Immunoblot analysis of L. tarentolae whole-cell lysates.
Blots of cell extracts from L. tarentolae wild-type (WT), revertant
(REV), and Sb(III)-resistant (RES) cell lines (1  107 parasites in
each lane) were probed with antisera to L. major TST, T. brucei T[SH]2
reductase (TryR), L. major T[SH]2 synthetase (TryS), L. major try-
paredoxin (TryX), L. major tryparedoxin peroxidase type I (TryP), and
L. major tryparedoxin peroxidase type II (TDPX).
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creased TryP expression was due to gene amplification (data
not shown).
An association between TryP and heavy metal resistance has
previously been established. In recent studies, Lin and col-
leagues described the concomitant overexpression of cytosolic
and mitochondrial TryP in laboratory-generated, arsenite-re-
sistant Leishmania amazonensis (17, 21). Arsenite-resistant
Leishmania parasites are often found to be cross-resistant to
Sb(III), and the mechanisms of resistance to both metalloids
are believed to share many common features (12, 14).
Overexpression of recombinant tryparedoxin peroxidase.
To confirm the role of TryP in Sb(III) resistance, the cytosolic
enzyme from L. major was overexpressed in wild-type (TarII),
Sb(III)-sensitive L. tarentolae. Western analysis of parasites
transfected with L. major TryP revealed an approximately 2.2-
fold increase in TryP at the protein level compared with wild-
type parasites and those transfected with the pIR1SAT vector
alone (Table 3). The overexpression of TryP was further con-
firmed when metabolism of H2O2 in crude lysates of these
pIR1SAT-LmTryP cloned transfectants (8.3 nmol min1
mg1) was found to be approximately twofold higher than that
in the vector-only control (4.3 nmol min1 mg1). Most im-
portantly, the TryP-overexpressing L. tarentolae cell line was
found to be significantly more resistant to Sb(III) (EC50,
22.7 
 0.8 g ml1; P  0.001) than either the wild-type cell
line (EC50, 7.3 
 0.4 g ml
1) or promastigotes containing the
empty vector (EC50, 9.24 
 0.4 g ml
1) (Table 3).
Overexpression of an inactive tryparedoxin peroxidase. In
previous studies, Flo¨he and colleagues have demonstrated that a
highly conserved arginine residue at position 128 of both the
Crithidia fasiculata (24) and L. donovani (8) TryPs is essential for
peroxidase activity. In both organisms, replacement of R128 with
an acidic residue resulted in a correctly folded TryP devoid of
activity. To determine whether peroxidase activity itself is central
to the Sb(III) resistance conferred by L. major TryP overexpres-
sion, a pIRSAT-LmTryP(R128D) construct was generated and
transfected into wild-type L. tarentolae. Western analysis of par-
asites expressing L. major TryP(R128D) revealed an approxi-
FIG. 3. Cellular location of elevated tryparedoxin peroxidase. Subcellular fractions of L. tarentolae promastigotes containing the large-granule
(LG), microsomal (MF), and cytosolic (C) fractions were prepared as described in Materials and Methods. Western blots of these equally loaded
fractions (30 g of protein in each lane) were probed with antiserum to L. major tryparedoxin peroxidase (type I). In addition, blots were stripped
and reprobed with antiserum to marker proteins for each subcellular fraction to demonstrate the purity of each fraction (LG, anti-Hsp60; C, anti-L.
major T[SH]2 synthetase; MF, anti BiP).
FIG. 4. Analysis of EC50 values for Sb(III) against TryP activity.
Peroxidase activities (H2O2) from the cell lysates of wild-type (open
circles), REV (closed circles), vector-only control (open squares),
TryP-overexpressing (closed squares), and inactive TryP(R128D)-
overexpressing (open triangles) cloned cell lines were plotted against
the EC50s for Sb(III). A linear regression was fitted to these data with
a correlation coefficient of 0.99. Data are the mean of triplicate mea-
surements 
 standard deviations.
TABLE 3. Comparison of Sb(III) sensitivity and tryparedoxin
peroxidase levels in wild-type, revertant, and











Wild type None 1 3.5 
 0.4 7.3 
 0.4
pIR1SAT 1 4.3 
 0.2 9.3 
 0.4
pIR1SAT-LmTryP 2.2 8.3 





 0.1 8.3 
 0.5
Revertant None 2.8 14.4 
 0.9b 56.5 
 1.9b
a As determined by densitometry of Western blots and compared to wild-type
level.
b P  0.0001 compared to wild-type value.




arch 8, 2014 by W







mately 3.3-fold increase in TryP at the protein level, in keeping
with the levels of overexpression seen in the pIR1SAT-L. major
TryP transfectants (Table 3). However, in this instance L. major
TryP(R128D) overexpression was not accompanied by a concom-
itant increase in the metabolism of H2O2 (4.45 nmol min
1
mg1) or by an increase in Sb(III) tolerance (EC50, 8.3 
 0.5 g
ml1).
TryP activity (H2O2) in these cloned, transgenic lines and
also in the parental wild-type and revertant lines was found to
directly correlate with Sb(III) resistance, with a correlation
coefficient of 0.99 (Fig. 4). The direct correlation between
peroxidase activity and resistance is of particular interest, since
it suggests that TryP overexpression may be the principal re-
sistance determinant in the revertant cell line. Not surprisingly,
TryP activity did not directly correlate with Sb(III) resistance
in the highly resistant Sb1.1 line, since resistance in this cell
line is known to be multifactorial (12). These findings confirm
that an enhanced ability to metabolize specific peroxide sub-
strates plays a direct and quantifiable role in the mechanisms
of Sb(III) resistance in these Leishmania parasites.
DISCUSSION
The relevance of elevated intracellular thiol levels, due to
overexpression of GCS and ODC, and an increased efflux of
thiol-Sb(III) conjugates, due to the overexpression of PgpA, in
high-level resistance is well defined (12, 25). However, the
involvement of TryP in resistance has not been reported pre-
viously. The data presented here establish for the first time that
overexpression of an active TryP directly contributes to the
multifactorial Sb(III) resistance mechanisms in Leishmania
tarentolae. Our observations with Sb(III)-resistant L. tarentolae
are broadly supported by the recent studies of Hsu and col-
leagues, who reported the overexpression of several compo-
nents of both the cytosolic and mitochondrial tryparedoxin
pathways in laboratory-generated, arsenite-resistant Leishma-
nia amazonensis (17, 21). TryPs form the backbone of parasite
antioxidant defenses. In our previous studies we have demon-
strated that Sb(III) has pleiotropic effects on Sb T[SH]2 me-
tabolism which severely compromise thiol redox homeostasis
within Sb(III)-sensitive parasites, leading to accumulation of
reactive oxygen species (ROS) (Fig. 5) (23, 41). Thus, inhibi-
tion of TryR, depletion of intracellular T[SH]2, and inhibition
of TryP, alone or in combination, could account for the in-
creased levels of ROS.
Overexpression of TryP could confer resistance to Sb(III) by
two mechanisms: by sequestration of Sb(III) to this abundant
protein (1 to 4% of the total protein in L. major [19]) or by
increased enzyme activity to reduce levels of ROS induced by
exposure to Sb(III). The former mechanism can be excluded,
since overexpression of a mutant TryP devoid of peroxidase
activity but maintaining a full complement of cysteine residues
failed to provide protection from Sb(III). Thus, peroxidase
activity of TryP is essential to confer resistance in these cell
lines. Preliminary studies indicate that Sb(III) binds to TryP
sulfydryl groups as well as the other components of the try-
paredoxin peroxidase system (TryR, T[SH]2, and TryX), but
we have yet to establish whether TryP is a specific target for
antimonials (S. Wyllie, J. Ko¨nig, and A. H. Fairlamb, unpub-
lished data). Although TryP has not yet been shown to be
essential in Leishmania parasites, RNA interference studies
have demonstrated that it is essential for the viability of blood-
stream T. brucei (40). Further studies should clarify these pos-
sibilities.
The use of Leishmania tarentolae is open to the criticism that
it is not a relevant model for clinically observed antimony
resistance. However, elevated thiol levels and amplification of
GCS and PgpA have been identified in clinical isolates (25,
33). In preliminary studies with some of these Sb-resistant
isolates, we have noted elevated levels of tryparedoxin perox-
idase (S. Wyllie, G. Mandal, M. Chatterjee, and A. H. Fair-
lamb, unpublished data). Collectively, these data suggest that
enhanced antioxidant defenses, through overexpression of
TryP, may well be a key feature of mechanisms of clinical
resistance to antimonial drugs.
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